Amitriptyline for Insomnia
Amitriptyline is not recommended for treating insomnia in adults. Despite widespread off-label use in clinical practice, major sleep medicine guidelines explicitly advise against its use due to insufficient evidence of efficacy and unfavorable risk-benefit profiles. 1, 2
Guideline Recommendations
The American Academy of Sleep Medicine (2017) and American College of Physicians (2016) found insufficient evidence to support antidepressants, including amitriptyline, for insomnia treatment. 3, 1
Current evidence-based guidelines carry a negative recommendation for amitriptyline, stating that harms outweigh benefits despite frequent off-label prescribing. 2
No randomized controlled trials exist evaluating amitriptyline specifically for insomnia, despite its common use in practice. 4
Recent Research Evidence
The most recent high-quality study (2025) provides the only placebo-controlled data on low-dose amitriptyline for insomnia:
At 6 weeks, amitriptyline (10-20 mg) showed statistically significant but not clinically relevant improvement compared to placebo (mean difference -3.4 points on Insomnia Severity Index, 95% CI -6.3 to -0.4). 5
From 12 weeks onward, no statistically significant differences were observed between amitriptyline and placebo. 5
Amitriptyline did not achieve clinically meaningful improvement or recovery rates compared to placebo at any time point. 5
In contrast, mirtazapine in the same trial demonstrated both statistically significant and clinically relevant improvements at 6 weeks. 5
FDA Labeling and Dosing
Amitriptyline is not FDA-approved for insomnia. 1, 6
The FDA label indicates amitriptyline is approved only for depression, with initial dosing of 75 mg daily in divided doses for outpatients, or 50-100 mg at bedtime as an alternative initiation strategy. 6
The "low doses" used off-label for insomnia (10-20 mg) are not supported by FDA labeling and represent empiric practice without regulatory approval. 6, 5
Safety Concerns
Amitriptyline carries significant safety risks that are particularly problematic in insomnia populations:
Anticholinergic effects (dry mouth, constipation, urinary retention, cognitive impairment) are especially concerning in older adults. 2
Observational data link tricyclic antidepressants and other hypnotics to increased risk of dementia (hazard ratio 2.34,95% CI 1.92 to 2.85), falls, fractures, and major injuries. 3, 2
Older adults should specifically avoid tricyclic antidepressants due to heightened fall risk and cognitive adverse effects. 2
One case report documented amitriptyline-induced insomnia, highlighting paradoxical effects. 7
Evidence-Based Alternatives
First-line pharmacologic options with robust evidence include:
Eszopiclone 2-3 mg provides the strongest evidence for both acute and long-term treatment with sustained efficacy beyond 4 weeks. 2
Suvorexant 10-20 mg (orexin receptor antagonist) improves sleep maintenance with better tolerability and preservation of natural sleep architecture. 2
Low-dose doxepin 3-6 mg is the only tricyclic with evidence for insomnia, specifically targeting sleep maintenance with favorable tolerability at this low dose. 2, 4
Clinical Bottom Line
Do not prescribe amitriptyline for insomnia. The 2025 randomized controlled trial definitively shows lack of clinically meaningful benefit, and guidelines consistently recommend against its use. 2, 5 If a tricyclic is desired for sleep maintenance, use doxepin 3-6 mg, which has specific evidence at low doses and avoids the higher anticholinergic burden of amitriptyline at typical antidepressant doses. 2, 4